Discovery of Novel Sertraline Derivatives as Potent Anti- Cryptococcus Agents

Wang Li,Zhaolin Yun,Changjin Ji,Jie Tu,Wanzhen Yang,Jian Li,Na Liu,Chunquan Sheng
DOI: https://doi.org/10.1021/acs.jmedchem.1c01845
IF: 8.039
2022-03-06
Journal of Medicinal Chemistry
Abstract:Treatment of life-threatening cryptococcal meningitis (CM) is highly challenging due to the limited efficacy of the available antifungal drugs. Antidepressant sertraline (SER) has been proposed to be a potential antifungal agent for CM. However, clinical studies indicated that SER failed to achieve the expected therapeutic effects. Herein, novel SER derivatives were designed by scaffold hopping, and they showed improved anticryptococcal activity both in vitro and in vivo. In particular, compound D16 was identified as a promising anti-CM agent with a new antifungal mode of action. It acted by blocking the biosynthesis of ergosterol through the inhibition of Δ5,6-desaturase. This study provides a new target and a drug-like candidate for CM treatment.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01845.Antifungal activity of compound D16 against 50 strains of Cryptococcus; MFC/MIC ratios of compound D16, SER, and AmB; BBB penetration in the PAMPA-BBB assay of FLC, SER, and compound D16; experimental procedure of the cytotoxicity assay; changes of the ergosterol content of C. neoformans H99 treated with different concentrations of FLC and amorolfine; comparison of sterol components of C. neoformans H99 treated with FLC, SER, and amorolfine at 2 μg/mL; sequences of primers in the RT-PCR assay; sources of strains; structural characterization of intermediates and target compounds; and HPLC spectra of compound D16 (PDF)Molecular formula strings of the target compounds (CSV)This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?